Bicycle Therapeutics, plc
https://www.bicycletherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bicycle Therapeutics, plc
Finance Watch: Lykos Implements 75% Workforce Reduction After FDA Rejection
Restructuring Edition: Lykos recruited a J&J veteran to help its slimmed-down staff resubmit its MDMA-based PTSD therapy. Also, Lexicon cut its field force by 50%, or 75 jobs; Viracta cut its solid tumor program and 23% of its workforce; and Boundless Bio streamlined with moderate job cuts.
Corbus Keeps Rising On ADC And Obesity Plans
The company is on a roll thanks to its challenge to Pfizer’s Padcev and competition with a potential obesity market gamechanger from Novo Nordisk.
Finance Watch: Cytokinetics Accesses Up To $1bn-Plus, Confirms No-Sale Plan
Public Company Edition: Cytokinetics executed a royalty financing deal for up to $575m and grossed $500m in a follow-on offering. Also, GSK grossed £1.25bn ($1.58bn) in sale of final Haleon shares, Bicycle raised $555m in a private placement and Apellis accessed up to $475m in debt.
Downturn Hit UK Biotech In 2023 But New Pension Funds Could Fuel Growth
Funding for UK biotechs shrank again last year but sector leaders see hope of green shoots in 2024.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Bicycle Therapeutics Limited
- Bicycle Therapeutics Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice